Earnings summaries and quarterly performance for Barinthus Biotherapeutics.
Executive leadership at Barinthus Biotherapeutics.
Board of directors at Barinthus Biotherapeutics.
Research analysts covering Barinthus Biotherapeutics.
Recent press releases and 8-K filings for BRNS.
Barinthus Biotherapeutics Merger Investigation Announced
BRNS
M&A
Legal Proceedings
- Monteverde & Associates PC is investigating Barinthus Biotherapeutics plc (NASDAQ:BRNS) in connection with its merger with Clywedog Therapeutics, Inc.
- Under the terms of the proposed transaction, Barinthus shareholders are expected to receive one share of common stock in the new combined company for each American Depository Share or ordinary share owned.
- Clywedog shareholders will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned.
Nov 19, 2025, 7:10 PM
Barinthus Bio Reports Q3 2025 Financial Results and Announces Merger Agreement
BRNS
Earnings
M&A
Guidance Update
- Barinthus Biotherapeutics plc reported a net loss of $14.6 million, or $(0.36) per share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held $75.7 million in cash, cash equivalents, and restricted cash.
- On September 30, 2025, Barinthus Bio announced a definitive merger agreement with Clywedog Therapeutics Inc. The combined company will be renamed Clywedog Therapeutics Holdings, Inc. and is expected to trade on NASDAQ under the ticker symbol CLYD.
- The transaction is anticipated to close in the first half of 2026, with the combined company's estimated cash runway extending through 2027.
- Key clinical milestones include single ascending dose data readout for VTP-1000 expected before the end of 2025, and multiple ascending dose data from the AVALON trial anticipated in the second half of 2026.
Nov 7, 2025, 12:34 PM
Barinthus Biotherapeutics plc Announces All-Stock Merger with Clywedog Therapeutics, Inc.
BRNS
M&A
New Projects/Investments
Guidance Update
- Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. have entered into a definitive all-stock merger agreement.
- The combined company will be renamed Clywedog Therapeutics, Inc. and is expected to trade on NASDAQ under the new ticker symbol "CLYD".
- The transaction is projected to close in the first half of 2026, with the combined company's cash runway estimated to extend through 2027.
- The combined company will advance a portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, with four key value-driving milestones expected within 18 months of closing.
- Following the Scheme Effective Time and prior to the Merger, Topco (the combined company) will commence a self-tender offer, with the aggregate consideration not exceeding $27,000,000.
Sep 30, 2025, 12:16 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more